Mandate

Vinge advises Nuevolution in connection with a directed share issue

May 25, 2018

The board of directors of Nuevolution has resolved on a directed new issue of shares, whereby Nuevolution will raise proceeds of approximately SEK 110 million, before issue costs.

The share issue is directed to a number of selected Swedish and international investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank AB (publ) and Redeye AB.

Nuevolution AB (publ) is a small molecule drug discovery biotech company. The company’s shares are admitted to trading on Nasdaq First North Premier.

Vinge’s team has consisted of Dain Hård Nevonen, David Andersson, Malte Hedlund and Stephanie Stiernstedt.

Related

Vinge advises EQT in connection with the sale of Eton

Vinge has advised EQT VII in connection with its sale of Eton to a consortium of private investors.
July 01, 2025

Vinge advises Triton in connection with the acquisition of Prenax

Vinge has advised Triton Smaller Mid Cap Fund II in connection with the acquisition of Prenax from LBO France and certain minority shareholders.
July 01, 2025

Vinge advises Impilo on the establishment of Impilo Healthcare

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Healthcare. The fund will have EUR 320m in commitments.
July 01, 2025